Nevertheless, the anti-cancer properties of FBXL2 activators like the small molecule BC-1258 46 will be adversely impacted by FBXL2-mediated IP3R3 degradation, likely limiting their application to PTEN-positive cancers. Here, ITPR3 is linked to cancer.